# Idgie Health reviews (2026): GLP-1 telehealth sellers | This GLP This seller calls its own microdosing approach off-label on the page that sells it, which few in this category do. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/reviews/idgie-health Updated: 2026-10-28 By [This GLP Editorial Team](https://thisglp.com/about) · Updated September 2026 Seller names the off-label part # Idgie Health review This seller calls its own microdosing approach off-label on the page that sells it, which few in this category do. ## The verdict Idgie Health prices a compounded semaglutide microdose at $134 a month, a tirzepatide microdose at $179, and an oral semaglutide tablet at $287. Its own product copy describes microdosing as an off-label approach rather than leaving the reader to work that out. **Disclosure:** This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. [How we make money](https://thisglp.com/disclosures). Category GLP-1 telehealth Molecule Semaglutide · Tirzepatide Form Injection · Oral Dose pricing Flat across doses States 50 Injection From $134/mo Oral From $287/mo Prescription Required Compounded Yes — not FDA-approved Idgie Health sells compounded semaglutide and compounded tirzepatide as microdose injections, and semaglutide as an orally dissolving tablet. The three figures read $134, $179 and $287 a month. Each is billed monthly and described as flexible. Three-month purchases were $377, $497 and $747 charged on the day of order. 1. ## Who writes the prescription, and what do they see? A prescription is required and the plans are sold as month-to-month with a three-month alternative. The tablet is listed on the program menu as a semaglutide and ondansetron combination, which names a second active ingredient rather than implying one. What an intake asks before a prescription is issued is not published. Coverage is published as fifty states. Treatment is arranged remotely and the products are described by dose class rather than by milligram. Microdosing means a weekly dose below the maintenance doses the approved labels set out. The ondansetron in the tablet is an antiemetic, included against the nausea that accompanies these molecules. Whether it reduces that nausea at the quantity used was not measured in the outcome trials. 2. ## What happens when the dose goes up? The published figure is one rate for the microdose product rather than a ladder. A reader who escalates past the microdose range is buying a different product rather than a higher tier of this one. What the next rung costs is not published beside these three. The three-month purchases are charged in full on the day they are placed. 3. ## What the price includes The monthly and the three-month routes are both published, which lets a reader see the whole choice. Semaglutide runs $134 monthly against $125 a month across three, and tirzepatide $179 against $165. The tablet is the expensive route at $287 monthly, or $249 a month across three. Every three-month figure is a single charge rather than a lower monthly bill. 4. ## What it claims, and what it cites All three products are compounded, so a pharmacy prepares them and no regulator reviews the finished dose form. Naming microdosing as off-label is accurate and unusual to print. The published weight-change results for [semaglutide](https://thisglp.com/research/semaglutide-cochrane-review) and [tirzepatide](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) came from label doses over sixty-eight and seventy-two weeks. What a microdose produces over the same period was not measured. ## Where it holds up, and where it does not - Strength: Seller names microdosing as off-label - Strength: Monthly and three-month figures both published - Strength: Second active ingredient named on the tablet - Limitation: Microdoses sit below the studied doses - Limitation: Three-month price is charged in full - Limitation: Tablet costs more than either injection ## What the evidence says about this kind of treatment The assessment above is about Idgie Health. These are about the drugs it sells, and they are traced to the primary literature. - [What happens to the dose, and to the side effects, over the first twenty weeks?](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1) - [How much of the weight lost is muscle, and what changes that?](https://thisglp.com/research/muscle-loss-on-glp1) - [What does the trial evidence show when treatment stops?](https://thisglp.com/research/stopping-glp1-and-weight-regain) Right for A reader who wants a seller to say plainly that a microdose is an off-label use before taking a payment for one. Wrong for A reader looking for the doses the outcome trials used, since every product priced here is a microdose or a tablet rather than a label-dose injection. ## The evidence behind what Idgie Health prescribes These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation. - [Cochrane Review of Semaglutide for Obesity: 18 Trials Graded](https://thisglp.com/research/semaglutide-cochrane-review) A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower. - [Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?](https://thisglp.com/research/tirzepatide-vs-semaglutide-which-works-better) In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points. ## How Idgie Health compares | Seller | Who it suits | Go | | --- | --- | --- | | Bayan Health | A reader weighing an injection against an oral preparation at one seller, where both routes carry the same monthly figure. | | | Enhance MD | A reader who wants the labs and the consultation inside one figure, and who can hold the four-week cycle in mind when comparing it with a monthly rate elsewhere. | | | Lean Meds | Readers willing to clarify the prescription and renewal details | | [Compare all providers side by side →](https://thisglp.com/best) More GLP-1 telehealth sellers reviews: [DrBrainRx](https://thisglp.com/reviews/drbrainrx) [DreamHug Medical](https://thisglp.com/reviews/dreamhug-medical) [DudeMeds](https://thisglp.com/reviews/dudemeds) [Eclipse Medical Wellness](https://thisglp.com/reviews/eclipse-medical-wellness) [Edessa](https://thisglp.com/reviews/edessa) [EdgeRx](https://thisglp.com/reviews/edgerx) Sponsored alternative SkinnyRx Readers choosing tirzepatide, the one line with a published standing rate ## Frequently asked What does off-label mean on this page? It means the dose is used in a way the approved label does not describe. Idgie Health applies the phrase to its own microdosing approach, on the page that sells it. Why is the tablet dearer than the injection? The tablet is $287 a month against $134 for the microdose injection. It is listed as a semaglutide and ondansetron combination, which is a different preparation rather than the same drug in another form. Is the three-month price a lower monthly rate? No. $377 is charged on the day of order and works out at $125 a month. The monthly plan bills $134 at a time and can be stopped sooner. Is Idgie Health expensive compared with other GLP-1 telehealth sellers? Idgie Health publishes a starting figure of $134/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Idgie Health below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes. Or [compare every seller we cover](https://thisglp.com/best). **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).